Novocral (Ceftazidime)

Ceftazidime works by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final stages of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and death of susceptible Gram‑negative organisms, including many resistant strains.

The exact dose of Novocral is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Dosing regimens are individualized and should follow the prescriber’s order and institutional protocols.

Safety data for ceftazidime during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To order Novocral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Novocral (ceftazidime) offers potent activity against many Gram‑negative organisms, especially Pseudomonas aeruginosa, and is more resistant to beta‑lactamases than earlier cephalosporins. Compared with cefepime, another fourth‑generation cephalosporin, ceftazidime has a narrower spectrum against Gram‑positive bacteria but similar efficacy against resistant Gram‑negative pathogens, making choice dependent on local susceptibility patterns.

Novocral should be stored at 2‑8 °C in a refrigerator, protected from light and never frozen. Keep the vial in its original packaging to maintain sterility. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration; discard if any abnormalities are observed.

Novocral is administered intravenously by slow infusion or intermittent injection, as directed by the prescriber. The infusion rate and duration depend on the dose and patient tolerance. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy, with appropriate monitoring for adverse reactions.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, renal toxicity especially in patients with pre‑existing kidney disease, and neurologic events like seizures at high plasma concentrations. Prompt recognition and medical intervention are essential if any of these events occur.

Novocral should be avoided in individuals with a documented allergy to ceftazidime, other cephalosporins, or penicillins. Patients with severe renal impairment require dose adjustment; use without adjustment may be unsafe. Additionally, it is contraindicated in patients with a history of severe, life‑threatening hypersensitivity reactions to beta‑lactam antibiotics.